BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32001681)

  • 1. Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia.
    Llorens F; Hermann P; Villar-Piqué A; Diaz-Lucena D; Nägga K; Hansson O; Santana I; Schmitz M; Schmidt C; Varges D; Goebel S; Dumurgier J; Zetterberg H; Blennow K; Paquet C; Baldeiras I; Ferrer I; Zerr I
    Nat Commun; 2020 Jan; 11(1):619. PubMed ID: 32001681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between lipocalin-2 and mild cognitive impairment or dementia: A systematic review and meta-analysis of population-based evidence.
    Li X; Wang X; Guo L; Wu K; Wang L; Rao L; Liu X; Kang C; Jiang B; Li Q; Li H; He F; Lu C
    Ageing Res Rev; 2023 Aug; 89():101984. PubMed ID: 37330019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease.
    Minta K; Brinkmalm G; Portelius E; Johansson P; Svensson J; Kettunen P; Wallin A; Zetterberg H; Blennow K; Andreasson U
    J Alzheimers Dis; 2021; 79(2):729-741. PubMed ID: 33337373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
    Nägga K; Gottfries J; Blennow K; Marcusson J
    Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
    Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
    J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia.
    Fredman P; Wallin A; Blennow K; Davidsson P; Gottfries CG; Svennerholm L
    Acta Neurol Scand; 1992 Feb; 85(2):103-6. PubMed ID: 1574982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
    Olsson B; Hertze J; Ohlsson M; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Zetterberg H; Blennow K; Hansson O
    J Alzheimers Dis; 2013; 34(3):673-9. PubMed ID: 23254629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.
    Adair JC; Charlie J; Dencoff JE; Kaye JA; Quinn JF; Camicioli RM; Stetler-Stevenson WG; Rosenberg GA
    Stroke; 2004 Jun; 35(6):e159-62. PubMed ID: 15105518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.
    Blennow K; Davidsson P; Wallin A; Gottfries CG; Svennerholm L
    Int Psychogeriatr; 1994; 6(1):13-22; discussion 59-60. PubMed ID: 8054491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and management of vascular cognitive impairment and dementia.
    Erkinjuntti T
    J Neural Transm Suppl; 2002; (63):91-109. PubMed ID: 12597611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of laminins in the cerebrospinal fluid obtained from patients with Alzheimer's disease and vascular dementia using a modified enzyme-linked immunosorbent assay.
    Matsuda K; Tashiro K; Hayashi Y; Monji A; Yoshida I; Mitsuyama Y
    Dement Geriatr Cogn Disord; 2002; 14(3):113-22. PubMed ID: 12218253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of inflammatory and hemostatic biomarkers in Alzheimer's and vascular dementia - A pilot study from a tertiary center in Northern India.
    Vishnu VY; Modi M; Garg VK; Mohanty M; Goyal MK; Lal V; Mittal BR; Prabhakar S
    Asian J Psychiatr; 2017 Oct; 29():59-62. PubMed ID: 29061429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flotillin is a Novel Diagnostic Blood Marker of Alzheimer's Disease.
    Abdullah M; Kimura N; Akatsu H; Hashizume Y; Ferdous T; Tachita T; Iida S; Zou K; Matsubara E; Michikawa M
    J Alzheimers Dis; 2019; 72(4):1165-1176. PubMed ID: 31683489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of new and classic CSF biomarkers in age-related dementias.
    Marchegiani F; Matacchione G; Ramini D; Marcheselli F; Recchioni R; Casoli T; Mercuri E; Lazzarini M; Giorgetti B; Cameriere V; Paolini S; Paciaroni L; Rossi T; Galeazzi R; Lisa R; Bonfigli AR; Procopio AD; De Luca M; Pelliccioni G; Olivieri F
    Aging (Albany NY); 2019 Apr; 11(8):2420-2429. PubMed ID: 31029057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
    Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
    de Jong D; Jansen RW; Kremer BP; Verbeek MM
    J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.